AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
Status:
Completed
Trial end date:
2021-04-08
Target enrollment:
Participant gender:
Summary
This is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate
the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with malignant
solid tumors, including lymphomas.